4142:TPE
Adimmune Corp
NT$15.85
arrow_downward
-1.86%(-0.30) 1D
11월 19일, 오후 1시 30분 8초 GMT+8 · TWD
search
모든 종목 코드
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_auto4142의 주요 통계 생성 중...
시가
NT$16.20
고가
NT$16.25
저가
NT$15.70
시가총액
68.08억
평균 거래량
109.29만
거래량
160.31만
주가수익률
91.85
52주 최고가
NT$21.50
52주 최저가
NT$15.65
EPS
NT$0.17
유통 주식수
2.35억
직원 수
564
시가
NT$16.20
고가
NT$16.25
저가
NT$15.70
시가총액
68.08억
평균 거래량
109.29만
거래량
160.31만
주가수익률
91.85
52주 최고가
NT$21.50
52주 최저가
NT$15.65
EPS
NT$0.17
유통 주식수
2.35억
직원 수
564
뉴스 기사
웹 소스 및 뉴스 파트너 제공
프로필
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Adimmune Corp에 관한 정보